688302 Hinova Pharmaceuticals Inc.
- 25.91
- +0.41+1.61%
Hinova Pharmaceuticals Inc. News
Announcement on voluntary disclosure of oral PROTAC drug HP518 intended for the treatment of androgen receptor (AR) positive triple-negative breast cancer granted Fast Track designation by the US FDA.
Announcement on voluntary disclosure of clinical data for the PROTAC drug under development HP518 to be released at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Legal Opinion of Beijing Junhe (Chengdu) Law Firm on the 2023 Annual General Meeting of Shareholders of Haichuang Pharmaceutical Co., Ltd.
2023 Annual General Meeting of Shareholders Meeting Materials
Announcement on adjustments to some initial public offering of shares
Announcement on the company's 2024 remuneration plan for directors, supervisors and senior management
Notice on requesting the shareholders' meeting to authorize the board of directors to issue shares to specific targets through simple procedures
Notice on convening the 2023 Annual General Meeting of Shareholders
2023 Board Audit Committee Performance Report
Independent Director Independence Self-Inspection Status Form - Peng Yongchen
Report on the performance of supervisory duties of accounting firms by the Audit Committee of the Board of Directors in 2023
2023 Internal Control Evaluation Report
Notice on using part of idle own funds for cash management
Announcement on purchasing liability insurance for the company and its directors, supervisors and senior management
Announcement of Resolutions of the Second Extraordinary General Meeting of Shareholders in 2023
Legal Opinion of Beijing Junhe (Chengdu) Law Firm on the 2023 Second Extraordinary General Meeting of Shareholders of Haichuang Pharmaceutical Co., Ltd.
Voluntary disclosure announcement on completion of the first clinical trial of the oral PROTAC drug HP518 tablets in China
Meeting materials of the 2nd Extraordinary General Meeting of Shareholders in 2023
Notice on amending the “Articles of Association” and part of the company\'s governance system
Analysis
Price Target
No Data
